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Tissue factor pathway inhibitor expression in human crescentic coagulation, is a circulating and endothelial-bound serine
glomerulonephritis. protease inhibitor that binds factor Xa and TF/factor
Background. Tissue factor (TF) pathway inhibitor (TFPI), VIIa complexes to form an inactive quaternary complex.the major endogenous inhibitor of extrinsic coagulation path-
Glomerular expression of TF is significantly up-regu-way activation, protects renal function in experimental cres-
lated in human crescentic glomerulonephritis (GN) [1];centic glomerulonephritis (GN). Its glomerular expression and
relationship to TF expression and fibrin deposition in human however, the role of TFPI in human GN has not been
crescentic GN have not been reported. previously studied.
Methods. Glomerular TFPI, TF, and fibrin-related antigen In vitro studies with monocytes have confirmed that(FRA) expression were correlated in renal biopsies from 11
their net procoagulant activity depends on the balancepatients with crescentic GN. Biopsies from 11 patients with
between TF and TFPI antigen expression [2]. In thethin basement membrane disease and two normal kidneys were
used as controls. normal human kidney, TFPI is found only in association
Results. TFPI was undetectable in control glomeruli but was with the endothelium of small interstitial vessels and is
detectable in interstitial microvessels. In crescentic biopsies,
negative in the glomerulus [3], in contrast to the constitu-TFPI was detected in cellular crescents and was more promi-
tive expression of TF in association with epithelial andnent in fibrous/fibrocellular crescents, indicating a correlation
with the chronicity of crescentic lesions. TFPI appeared to be mesangial cells [4]. In vivo administration of TFPI pro-
associated with macrophages but not endothelial or epithelial tects from inflammatory tissue injury associated with en-
cells. TFPI was generally undetectable in regions of the glomer- dotoxic shock [5] and spinal cord ischemia [6] and is
ular tuft with minimal damage. In contrast, TF and FRA were
currently under trial in humans with septic shock.strongly expressed in regions of minimal injury, as well as in
In experimental crescentic GN in rabbits, glomerularmore advanced proliferative and necrotizing lesions. Despite
prominent TF expression, FRA was less prominent in fibrous/ TFPI is constitutively expressed and is down-regulated
fibrocellular crescents in which TFPI expression was maximal. early in the disease at the time of maximal up-regulation
Conclusions. These data suggest that TFPI is strongly ex- of glomerular TF activity [7]. This may contribute to thepressed in the later stages of crescent formation and is inversely
greater increase in TF activity compared with TF antigencorrelated with the presence of FRA in human crescentic GN.
at this early stage of the disease. Infusion of recombinantThis late induction of TFPI may inhibit TF activity and favor
reduced fibrin deposition in the chronic stages of crescent for- human TFPI significantly reduced fibrin deposition, pro-
mation. teinuria, and renal impairment, whereas functional inhi-
bition of endogenous TFPI in vivo with an anti-TFPI
antibody significantly increased glomerular fibrin deposi-
Tissue factor (TF) is the principle initiator of the ex- tion and exacerbated renal impairment [7].
trinsic coagulation pathway, the major pathway for ini- Intraglomerular fibrin deposition and enhanced TF
tiating fibrin deposition in vivo. Tissue factor pathway expression are prominent in human crescentic GN. Fi-
inhibitor (TFPI), the principle inhibitor of TF-initiated brin is deposited early and is critical for disease progres-
sion [8]. Tipping, Dowling and Holdsworth demonstrated
increased TF activity in glomeruli from two patients whoKey words: fibrin, crescents, coagulation, pro-coagulant activity, pro-
teinuria, renal injury. died soon after presentation with severe acute crescentic
GN [1]. In experimental crescentic GN, fibrin is an im-Received for publication April 1, 1998
portant chemotactic stimulus for macrophage recruit-and in revised form September 9, 1998
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[10] or streptokinase [11] preserves renal function with- Assessment of interstitial lesions
out reducing proteinuria, macrophage recruitment, or The extent and distribution of TFPI expression in in-
mesangial hypertrophy. Functional inhibition of TF with terstitial areas were assessed in a blinded protocol. The
an anti-TF antibody ameliorates glomerular fibrin depo- number of positively stained blood vessels per randomly
sition and glomerular injury in experimental GN [12]. selected 1 mm2 areas was counted using a lattice graticule
eyepiece.These experimental data suggest that dysregulation of
human TFPI/TF balance early in the disease process is
Immunoperoxidase histochemistrylikely to be an important role in the initiation of patho-
Biopsy segments were fixed by neutral-buffered for-logical glomerular fibrin deposition and the exacerbation
malin or in mercuric formalin following immersion inof glomerular inflammation in crescentic GN. Therefore,
Dubbos-Brazil solution. Tissue was embedded in paraf-we sought to assess the expression of TFPI in relation
fin and cut into serial sections. Sections of placenta wereto glomerular fibrin deposition and TF expression in
used as positive control both for TFPI and TF.various stages of glomerular injury in patients with cres-
Fibrin-related antigen (FRA) was detected directlycentic GN.
using a monospecific peroxidase-conjugated rabbit anti-
human fibrinogen antibody (Dako, Carpinteria, CA,
USA) by direct immunoperoxidase staining as describedMETHODS
previously [15]. Sections from paraffin-embedded tissuePatients
were dewaxed and rehydrated. After enzyme digestion
Renal biopsies from 11 patients with crescentic GN with 0.025 g protease VIII (Sigma, Poole, Dorset, UK)
of diverse etiology were studied and compared with 11 in 100 ml phosphate-buffered saline (pH 7.2) for two
patients with thin basement membrane disease (TBMD; minutes, endogenous peroxidase activity was quenched
control group). Biopsies from patients with crescentic in methanol containing 0.3% hydrogen peroxide for 20
minutes. Sections were first incubated with normal rabbitGN were performed before or within 48 hours of the
serum (Vector Laboratories, Burlingame, CA, USA) forcommencement of treatment. Two sections of normal
10 minutes and were then incubated with peroxidase-human kidney were obtained from cadaveric renal trans-
labeled rabbit antihuman fibrinogen antibody, and colorplant donors whose kidneys were technically unsuitable
was developed with 3,3-diaminobenzidine in 0.01%for transplantation.
H2O2. Sections were counterstained with hematoxylin.
Tissue factor pathway inhibitor and TF were detectedClassification of glomerular histology
by indirect immunoperoxidase, as described previouslyThe glomerular lesions in patients with crescentic GN
[16], using monoclonal antihuman TFPI (American Di-
were subclassified as necrotizing lesions, proliferative agnostica Inc., Greenwich, CT, USA.) and monoclonal
lesions, and crescent formation and were classified ac- antihuman TF (HTF1-7B8; donated by Dr. S. Carson,
cording to the World Health Organization Monograph Denver, CO, USA) [17] antibodies. Briefly, sections were
[13]. The intensity of staining in the segment of the glo- dewaxed and digested with protease VIII (Sigma), and
meruli scored on a scale from 0 to 31. Glomeruli that endogenous peroxidase activity was quenched as men-
did not have proliferation, necrosis, or crescent forma- tioned earlier here. Sections were incubated with the
tion were classified as having minor injury. These glomer- primary antibody for one hour, then with biotinylated
uli were considered to represent the earliest phase of horse antimouse IgG antibody (Vector Laboratories)
for 10 minutes, and then with avidin-DH-biotinylateddisease progression. Necrotizing and proliferative seg-
horseradish peroxidase complex (Vactastain ABC kit;ments of glomeruli were assessed separately from other
Vector Laboratories) for 15 minutes. After the color wasglomerular lesions and were considered together to rep-
developed with 3,3-diaminobenzidine in 0.01% H2O2, theresent the next stage of disease progression. Glomeruli
sections were counterstained with hematoxylin.were classified as having cellular crescents, if their cres-
The intensity of staining in the segment of the glomer-cents were predominantly cellular with minimal scarring.
uli was scored on a scale from 0 to 31. Glomeruli inCrescents in which the majority of the crescent was acel-
which deposition was not different from background
lular were classified as fibrocellular crescents. Crescents were scored 0. Glomeruli with light staining were scored
having no cellular component were classified as fibrous 11. Glomeruli with medium staining were 21 , and glo-
and were considered to represent the final stage of cres- meruli with intense staining were scored 31.
cent formation. TBMD was diagnosed in patients with
Assessment of the cellular localization of tissue factorisolated microscopic hematuria and normal light micros-
pathway inhibitorcopy and immunohistochemical findings when their
basement membrane thickness was less than 250 nm (by To assess the cellular origin of TFPI, colocalization
studies were performed according to previous methodselectron microscopy) [14].
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Table 2. Clinico-pathologic diagnoses in patients with crescentic GNTable 1. Clinical and laboratory data in patients with crescentic
glomerulonephritis (GN) and thin basement
Type ofmembrane disease (TBMD)
Patient immune deposit Clinical diagnosis ANCA
Patient group TBMD Crescentic GN
1 Anti-GBM Goodpasture’s
2 Anti-GBM Goodpasture’sNo. of patients 11 11
Age years 38 6 11 48 6 20 3 Immune complex Henoch-Scho¨nlein purpura
4 Pauci-immune Microscopic polyarteritis pMale/female 4/7 7/4
Urinary RBC log/ml 5.07 6 0.50 5.36 6 0.78 5 Pauci-immune Wegener’s granulomatosis c
6 Pauci-immune Wegener’s granulomatosis cUrinary protein g/day 0.2 6 0.2 4.8 6 2.8a
Plasma creatinine 0.09 6 0.01 0.49 6 0.38b 7 Pauci-immune Microscopic polyarteritis p
8 Pauci-immune Rapidly progressive GNCrescent formation % 0 74.3 6 23.4c
9 Pauci-immune Microscopic polyarteritis pAbbreviations are: No., number; RBC, red blood cells. Data are expressed
10 Pauci-immune Wegener’s granulomatosis cas the mean 6 sd.
11 Pauci-immune Microscopic polyarteritis paP , 0.01, bP , 0.005, cP , 0.0001 between the two groups
Abbreviations are: GBM, glomerular basement membrane; ANCA, anti-neu-
trophil cytoplasmic antibody; GN, glomerulonephritis.
[7]. Briefly, sections were incubated with monoclonal anti-
human TFPI antibody followed by alkaline phosphatase-
anti-glomerular basement membrane disease (with posi-labeled sheep antirabbit Ig antibody (Selinus Labora-
tive anti-glomerular basement membrane serology), onetories, Melbourne, Australia) and alkaline phosphatase-
patient had the clinical features of Henoch-Scho¨nleinantialkaline phosphatase complex (Silenus Laboratories).
purpura, and the remaining eight patients all had renalColor was developed by incubation with Fast Red TR/
vasculitis, with systemic inflammatory illness and positiveNaphthol AS-MX (Sigma). Sections were then stained
anti-neutrophil cytoplasmic antibody serology, with orusing horseradish peroxidase-conjugated monoclonal
without respiratory tract involvement.antihuman antibodies for macrophages (anti-CD14 anti-
body; Silenus), endothelial cells (anti-CD34; Dako), or Tissue factor pathway inhibitor expression
epithelial cells (anticytokeratin; Boehringer Mannheim, in glomeruli
Mannheim, Germany). Staining was developed with 3,3-
Tissue factor pathway inhibitor was undetectable in
diaminobenzidine/H2O2, and sections were counter- glomeruli from the two normal nephrectomy specimens
stained with hematoxylin. (not shown). Tissue factor pathway inhibitor was also
undetectable in glomeruli of patients with TBMD (Fig.Statistical methods
1A). In patients with crescentic GN, a total of 130 glo-
The proportion of TFPI-positive staining glomerular meruli was examined from 11 patients (a mean of 11.8
lesions was compared by the chi-squared test or unpaired glomeruli per biopsy, range 5 to 29). The mean propor-
Student’s t-test. tion of crescentic glomeruli was 74.3 6 23.4% per patient.
All biopsies showed glomeruli at various stages of cres-
cent formation. The TFPI staining at each stage of devel-RESULTS
opment of glomerular lesions is shown in Table 3. A totalClinical features
of 26 glomeruli from 9 of the 11 patients had glomeruli
Table 1 summarizes the clinical data of the TBMD showing minor injury. Tissue factor pathway inhibitor
(control) patient group and crescentic GN patient group. was not detected in any of these glomeruli (Fig. 1B).
The TBMD group had a mean age of 38 6 11 years with Proliferative and/or necrotizing lesions were observed
a 4:7 male:female ratio. All patients had asymptomatic in a total of 16 glomeruli from 10 of the 11 patients.
microscopic hematuria [5.06 6 0.50 urinary red blood Seven glomeruli had crescentic lesions in addition to
cell (RBC) log/ml; normal being less than 4] without their necrotizing and/or proliferative lesions. In glomer-
significant proteinuria (mean 0.2 6 0.2 g/day) or renal uli with necrotizing and/or proliferative lesions, TFPI
impairment (serum creatinine 0.09 6 0.01 mmol/liter). was not observed on capillary endothelia, but stained
No significant difference was found in either the age or weakly in the mesangia in 5 of 16 glomeruli. Cellular
urine RBC counts between the two groups. Table 2 shows crescents were observed in 10 of the 11 GN patients,
the underlying diseases in the crescentic GN group. The involving a total of 24 glomeruli. Tissue factor pathway
mean age of this group was 48 6 20 years and the male:fe- inhibitor was detected in 11 of these 24 crescentic glo-
male ratio was 7:4. These patients were all in their first meruli, representing 7 of the 11 patients. Tissue factor
presentation with acute disease typified by severe acute pathway inhibitor staining was of moderate intensity
renal failure (creatinine 0.49 6 0.38 mmol/liter), micro- within the cellular crescents but was weak or negative
scopic hematuria (urinary RBC 5.36 6 0.78 log/ml), and in associated glomerular tufts (Fig. 1C). Fibrocellular
and fibrous crescents were present in all 11 patients, inheavy proteinuria (4.8 6 3.8 g/day). Two patients had
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Fig. 2. Pathological features in focal and necrotizing glomerular lesions. A necrotic lesion (arrow) in a glomerulus from a patient with crescentic
GN (A, silver methenamine/Masson’s trichome stain). This type of lesions demonstrated prominent fibrin deposition (arrow, B) and TF expression
(C). TFPI was undetectable in the majority of glomeruli with these lesions (D). (B–D) Immunoperoxidase. Magnification 3400 in each case.
a total of 71 glomeruli. Intense TFPI staining was ob- Cellular localization of tissue factor pathway inhibitor
in fibrocellular and cellular crescentsserved in all of these fibrous/fibrocellular crescents (Fig.
1D). The prevalence of TFPI positivity was significantly Tissue factor pathway inhibitor was not detected on
greater fibrous/fibrocellular crescents than in necrotizing cells staining positive for epithelial cell markers (cytoker-
or proliferating lesions (P , 0.0001) or glomeruli with atin; Fig. 1E). Tissue factor pathway inhibitor was also
undetectable on glomerular endothelial cells. In fibrouscellular crescents (P , 0.0001).
b
Fig. 1. Tissue factor pathway inhibitor (TFPI) expression in human glomeruli. TFPI (brown reaction product) was undetectable in glomeruli from
patients with TBMD (A). TFPI was also undetectable in glomeruli with minor injury in patients crescentic GN, but was strongly expressed on
small interstitial vessels (arrow, B). Moderate TFPI expression was detected in some cellular crescents, but expression was weak or negative in
associated glomerular tufts (C). Strong TFPI expression was observed in the fibrous/fibrocellular crescents (D). TFPI (blue reaction product,
arrow) did not colocalize with glomerular epithelial cells (brown reaction product; E). In contrast, colocalization (arrow) of TFPI (blue reaction
product) was observed with some macrophages (brown reaction product; F). (A–D) Immunoperoxidase. (E and F) Immunoperoxidase and
immunoalkaline phosphatase. Magnification 3400 in each case.
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Table 4. Comparison of median TFPI, TF and FRA staining levelsTable 3. TFPI positivity in histological subgroups of glomeruli from
patients with crescentic GN at each stage of lesion progression
LesionLesion
Minor Necrotising/ Cellular FibrousMinor Necrotising/ Cellular Fibrous
injury proliferating crescent crescent injury proliferating crescent crescent
Patient 2 1 2 1 2 1 2 1 TFPI 0 11 11 31
TF 31 31 31 21
1 1 0 1 0 1 2 0 7 FRA 31 31 21 11
2 0 0 0 0 1 2 0 2
Abbreviations are: TFPI, tissue factor pathway inhibitor; TF, tissue factor;3 2 0 1 0 3 3 0 3
FRA, fibrin-related antigen.4 0 0 2 0 1 1 0 3
5 7 0 0 1 1 0 0 21
6 0 0 2 0 1 0 0 2
7 3 0 1 0 0 0 2 5
8 2 0 2 2 1 1 0 11
sclerotic vessels in one patient, but stained strongly in9 1 0 1 1 1 1 0 4
10 5 0 2 0 3 0 0 3 the interstitial microvasculature in all of the biopsies
11 5 0 1 1 0 1 0 8 from patients with crescentic GN. Tissue factor pathway
Total 26 0 11 5 13 11 2 69 inhibitor staining was particularly prominent in small
Abbreviations are: TFPI, tissue factor pathway inhibitor; GN, glomerulone- arteries with vasculitis and in the areas with cellular
phritis. The histological subgroups are defined in the Methods section.
infiltration and interstitial fibrosis (Fig. 1B). The mean
density of TFPI-positive interstitial vessels in biopsies
with crescentic GN (7.3 6 4.8 mm22) was significantly
greater than in patients with TBMD (1.2 6 2.1 mm22,and fibrocellular crescents, TFPI staining was colocalized
P , 0.001).to cells that stained positive with the macrophage mark-
ers CD14 (Fig. 1F).
DISCUSSIONCorrelation of glomerular tissue factor pathway
inhibitor, tissue factor, and fibrin during Fibrin is a prominent participant in crescentic forms
disease progression of human GN. Experimental models also demonstrated
early deposition of fibrin during the evolution of cres-The relationship between TFPI, TF, and FRA expres-
centic GN. The important functional role of fibrin insion and the phase of crescent evolution was similar for
the generation of crescents and deterioration of renaleach patient (Table 4). Tissue factor was detected on
function in experimental crescentic GN has been con-mesangial cells and epithelial cells but not on endothelial
firmed by demonstrating the beneficial effects of defi-cells in glomeruli from normal kidneys and patients with
brinogenation and fibrinolytic therapies [10, 11]. FibrinTBMD. Fibrin was undetectable in these tissues.
in Bowman’s space is an important chemotactic stimulusIn patients with crescentic GN, glomeruli with minor
for macrophage recruitment into crescents [9]. Althoughinjury demonstrated strong FRA TF (31) and TF (31)
less extensively studied in humans, the beneficial effectsstaining. In proliferating and necrotizing lesions (Fig.
of ancrod (a defibrinating agent) in patients with lupus2A), FRA (Fig. 2B) and TF (Fig. 2C) were strongly
nephritis also indicate an important functional role forpositive (31), whereas TFPI was either absent or stained
fibrin [18].weakly (Fig. 2D). In glomeruli with cellular crescents,
Fibrin deposition in crescentic GN is the result ofFRA was moderately intense (21), whereas TFPI was
local activation of the extrinsic coagulation pathway [12].only weakly positive or absent (Fig. 1C). Fibrin-related
Tissue factor and TFPI play pivotal roles in controllingantigen was also seen in the Bowman’s space of glomeruli
activation of this pathway. Tissue factor has been demon-involved by these lesions. Fibrin-related antigen (11)
strated to be up-regulated in both human and experimen-staining and TF (12) staining in the fibrous and fibrocel-
tal GN. Increased TF activity in glomeruli is an earlylular crescents were less than that observed in any other
event in the evolution of crescentic GN in rabbits andstage of crescent development.
precedes fibrin deposition [19]. In rabbits, TFPI antigen
Tissue factor pathway inhibitor staining in is expressed in the normal kidney in the glomerular endo-
the interstitium thelium and mesangial cells and in the interstitial capil-
lary network. Exacerbation of crescent formation andTissue factor pathway inhibitor is present in the inter-
renal injury following treatment with an anti-TFPI anti-stitial microvasculature in normal kidney tissue and in
body demonstrates the important role for endogenouspatients with TBMD (not shown). In TMBD, TFPI stain-
TFPI in crescentic GN [7].ing was regularly observed in arteriosclerotic blood ves-
Tissue factor pathway inhibitor was expressed exclu-sels, which were present in 5 out of 11 patients. Tissue
factor pathway inhibitor was not detectable in arterio- sively on microvessels in the renal interstitium of patients
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with TBMD, consistent with previous limited reports of calized with macrophages in crescents. Human macro-
the distribution of TFPI in the normal human kidney phages are known to express TF and TFPI on their cell
[3]. The lack of detectable TFPI in human glomeruli surface [2]. In experimental GN, TF is shed from cells
contrasts with the findings in rabbit glomeruli and may within crescents [7] and appears in the urine [20], and
reflect the sensitivity of the currently available detecting TFPI bound to TF as it is shed may contribute to its
antibodies in these two species. In interstitial areas, TFPI accumulation in acellular regions of crescents. In human
is also more prominent in the rabbit than in humans. atheromatous plaques, TF and TFPI colocalize in acellu-
In patients with crescentic GN, glomeruli demon- lar regions of intimal lesions [21]. Epithelial cells in cres-
strated a range of histologic lesions at various stages cents and the glomerular tuft did not colocalize with
of evolution of crescents within a single biopsy. The TFPI. In a primate model of acute sepsis-induced lung
glomeruli with minor injury had an inflammatory cell injury, TFPI expression was demonstrated on lung epi-
infiltrate in the glomerular tuft, increased TF expression thelial cells [22], however, there are no reports of TFPI
and fibrin deposition, and were considered to represent production by human cells of epithelial origin. Despite
the first stage in evolution toward crescent formation. the capacity of human microvascular endothelial cells
Tissue factor pathway inhibitor was not expressed in to produce TFPI (abstract; Bajaj et al, Blood 82(Suppl
these glomeruli. This lack of TFPI expression associated 1):271a, 1993) [23], its expression on endothelial cells
with maximal up-regulation of TF and significant fibrin in the tufts of glomeruli with fibrocellular and fibrous
deposition in glomeruli would be consistent with maxi- crescents could not be demonstrated. It is thus probable
mal activation of the extrinsic coagulation pathway at that the TFPI seen in the crescents is derived from infil-
this stage of the disease. trating macrophages.
Tissue factor pathway inhibitor was undetectable in The up-regulation of TFPI during the late phase of
most glomeruli with proliferative and necrotic lesions, crescent formation suggests that it may have a role in
and was minimally up-regulated in those occasional posi- scarring or healing. Recently, proinflammatory effects
tively stained lesions. Tissue factor expression remained of TF, which appear independent of its procoagulant
strongly up-regulated in these glomeruli, and the balance
function, have been demonstrated in experimental cres-
of TFPI and TF at this stage would continue to strongly
centic GN [12]. Up-regulation of TF precedes fibrin de-promote fibrin deposition, which was maximal in these
position and the development of scarring in experimentalglomeruli. These lesions were considered to represent
hydronephrosis [24]. The binding of factor VIIa to TFan early phase in the evolution of crescents. The maximal
may be an important intracellular signaling mechanismfibrin deposition in these precrescentic lesions is consis-
that increases reactive oxygen species production bytent with findings in experimental GN that fibrin deposi-
macrophages (abstract; Cunningham et al, J Am Soction precedes crescent formation [19].
Nephrol 8:470A, 1997). TFPI may have important anti-The most prominent expression of TFPI was seen
inflammatory effects via its role as the key endogenouswithin crescents. Tissue factor pathway inhibitor was
inhibitor of TF. This is supported by the observationsmoderately expressed in approximately half of the cellu-
that in vivo administration of TFPI attenuates experi-lar crescents examined. Weak expression was occasion-
mental models of injury, including crescentic GN [7],ally observed in the tuft of glomeruli with cellular cres-
endotoxic shock [5], and spinal cord ischemia [6].cents. At this stage, TF expression remained strong and
From the findings of this study, we conclude that glo-fibrin deposition, which remained predominantly in the
merular TFPI is dysregulated within the glomerulus inglomerular tuft, appeared less than in early lesions. Tis-
the early stages of disease when there is significant fibrinsue factor pathway inhibitor expression was maximal in
deposition. Interstitial TFPI expression correlated withfibrocellular and fibrous crescents, and expression in the
atherosclerosis and perivascular cellular infiltrate. TFPIglomerular tuft of these glomeruli was the most strongly
is up-regulated in the fibrotic crescents. Treatment withobserved in this region of the glomerulus at any stage.
TFPI or the discovery of agents that induce earlier TFPIIn fibrocellular and fibrous crescents, TF expression ap-
peared to be less than in other lesions, and fibrin deposi- up-regulation is a potential novel therapeutic interven-
tion, again predominantly in the glomerular tuft, was tion in human crescentic GN, as it acts by inhibiting
substantially reduced. These findings indicate a shift in coagulation and fibrin deposition and the associated in-
the TF/TFPI balance away from the strong procoagulant flammation and scarring without the bleeding complica-
environment in the earlier lesion in patients developing tions associated with currently available therapies.
crescentic GN and may reflect reparative processes in
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